AMICUS THERAPEUTICS INC. - COMMON STOCK

Amicus Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

28 May 2021 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases

21 May 2021 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates

10 May 2021 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021

07 May 2021 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development

06 May 2021 06:00:02 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 24th Annual Meeting

05 May 2021 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease

03 May 2021 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics Recognized as a Great Place to Work® in Europe

28 Apr 2021 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021

26 Apr 2021 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Presentation and Posters at the 2021 MDA Clinical & Scientific Conference

15 Mar 2021 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates

01 Mar 2021 06:00:02 By Nasdaq GlobeNewswire

Amicus Therapeutics to Present at Upcoming Investor Conferences

18 Feb 2021 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics to Announce Full-Year 2020 Financial Results on March 1, 2021

17 Feb 2021 06:00:01 By Nasdaq GlobeNewswire

Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study

11 Feb 2021 15:01:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021

08 Feb 2021 13:30:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021

08 Feb 2021 13:30:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium™ 2021

21 Jan 2021 06:00:00 By Nasdaq GlobeNewswire

Amicus Therapeutics Reports Preliminary 2020 Revenue and Provides 2021 Outlook

11 Jan 2021 06:00:01 By Nasdaq GlobeNewswire

Amicus Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

05 Jan 2021 06:00:01 By Nasdaq GlobeNewswire